Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01011530 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of MLN4924 in Adults With Melanoma
A Phase 1 study of Metastatic Melanoma, sponsored by Millennium Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 37
- Enrollment target
- 1
- Study location
NCT01011530: Completed Phase 1 study of Metastatic Melanoma, sponsored by Millennium Pharmaceuticals.
NCT01011530 is a Phase 1 study of Metastatic Melanoma that has completed, run by Millennium Pharmaceuticals. The registered enrollment target is 37 participants, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (55% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01011530, a Phase 1 study of Metastatic Melanoma, has completed, sponsored by Millennium Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 37 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.
Conditions Studied
Interventions
- DRUG MLN4924
Study Locations (1)
California
- The Angeles Clinic and Research Institute - Santa Monica
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2009-12 |
| Est. Completion | 2013-01 |
| Phase | Phase 1 |
What the finished NCT01011530 record still lists
NCT01011530 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 83-participant average among 91 other Metastatic Melanoma trials with a reported enrollment target (55% lower).
The record links to 1 condition, with Metastatic Melanoma appearing as the primary indexed condition, and to 1 intervention - of which MLN4924 is the first listed.
NCT01011530 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT01011530 about?
NCT01011530 is a clinical study titled "Dose Escalation Study of MLN4924 in Adults With Melanoma". This is an open-label, multicenter, phase 1, dose escalation study that will evaluate the safety profile, establish Maximum Tolerated Dose (MTD), and inform the recommended phase 2 dose of MLN4924 as well as evaluate antitumor activity in patients with metastatic melanoma.
What is the current status of trial NCT01011530?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 37 participants. The study started on 2009-12. Estimated completion is 2013-01.
What conditions does trial NCT01011530 study?
This clinical trial studies the following conditions: Metastatic Melanoma.
What interventions are being tested in trial NCT01011530?
The interventions under investigation include: MLN4924 (DRUG).
Who is sponsoring clinical trial NCT01011530?
This trial is sponsored by Millennium Pharmaceuticals, which has 135 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01011530 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Metastatic Melanoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT01011530's enrollment target sits among peer trials
37 45th of 91 higher than 46 of 91 other Metastatic Melanoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Metastatic Melanoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Therapeutic Drug Monitoring-Based Atezolizumab Dosing
RECRUITING · Phase 1
-
A Study to Investigate the Safety and Efficacy of IOV-3001 in Adults With Advanced Melanoma Who Will Receive Lifileucel
RECRUITING · Phase 1
-
Safety of AV-MEL-1 With Anti-PD-1 Therapy in Metastatic Melanoma
RECRUITING · Phase 1
-
Intralesional Influenza Vaccine for the Treatment of Stage I-IV Melanoma
RECRUITING · Phase 1
-
A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, or Dedifferentiated Liposarcoma
RECRUITING · Phase 1
-
A Study to Investigate the Efficacy and Safety of an Infusion of IOV-4001 in Adult Participants With Unresectable or Metastatic Melanoma or Stage III or IV Non-small-cell Lung Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia